Novel broad-spectrum coronavirus mRNA vaccine and preparation method thereof

By designing an mRNA vaccine containing multiple RBD and Fc fragments of the novel coronavirus, the problem of existing vaccines failing to produce broad-spectrum neutralizing antibodies has been solved, achieving an effective immune response to mutations in the novel coronavirus and improving the vaccine's broad-spectrum and immunogenicity.

CN118956920APending Publication Date: 2024-11-15CHANGCHUN BCHT BIOTECH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310544651.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing COVID-19 vaccines cannot produce broad-spectrum neutralizing antibodies and are unable to effectively combat coronavirus mutations, resulting in poor vaccine efficacy.

Method used

An mRNA vaccine was designed, comprising mRNA molecules encoding multiple receptor-binding domain (RBD) fragments of the novel coronavirus and immunoglobulin Fc fragments. The stability and translation efficiency of the mRNA were optimized by linker linkage, and the mRNA was encapsulated with lipid nanoparticles to form a broad-spectrum novel coronavirus mRNA vaccine.

Benefits of technology

It significantly improved the broad-spectrum and immunogenicity of neutralizing antibodies against the novel coronavirus in serum, enhanced the levels of cellular and humoral immune responses, and provided an effective strategy to combat viral mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to a novel broad-spectrum coronavirus mRNA vaccine and a preparation method thereof, in particular to a special design method of the novel broad-spectrum coronavirus mRNA vaccine. The present invention also provides an mRNA molecule encoding a sequence comprising a plurality of novel coronavirus receptor binding domain (RBD) fragments and an immunoglobulin Fc fragment linked to the plurality of novel coronavirus RBD fragments. The invention also provides a broad-spectrum novel coronavirus mRNA vaccine composition, and application of the mRNA molecule, the mRNA vaccine or the mRNA vaccine composition in preparation of medicines for preventing / treating diseases caused by novel coronavirus infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of bioengineering and immunity, and specifically, to a broad-spectrum novel coronavirus mRNA vaccine and a preparation method thereof, in particular a special design method for a broad-spectrum novel coronavirus mRNA vaccine. Background Art

[0002] The main clinical manifestations of novel coronavirus infection are fever, fatigue, dry cough, and inflammatory reactions in the upper and lower respiratory tracts, with most patients being asymptomatic.

[0003] Studies have shown that the S protein of the new coronavirus is closely related to the virus invading cells. The S protein consists of two domains. The part close to the N-terminus forms a spherical domain, and the part close to the C-terminus forms a membrane-penetrating rod-shaped domain. After the S protein precursor is synthesized in the host cytoplasm, it will be cut into S1 (spherical part) and S2 (rod-shaped part). Among them, the S1 part is involved in the recognition and binding of the receptor, which contains the receptor binding domain (RBD), and the S2 part is involved in the virus invading the host cell.

[0004] The new coronavirus vaccine is one of the most promising methods to control the epidemic. Currently, there are nine types of new coronavirus vaccines on the market worldwide. However, due to the frequent mutation of the new coronavirus and the inability of various vaccines to produce broad-spectrum neutralizing antibodies, they are not very effective in dealing with virus mutations. Summary of the invention

[0005] The present invention provides a Design of mRNA vaccine for novel coronavirus , as well as the new coronavirus mRNA vaccine constructed based on this design scheme, greatly improved the broad spectrum and immunogenicity of the new coronavirus neutralizing antibodies in the serum after immunization, while effectively improving the efficiency of antigen presentation, thereby improving the level of cellular immunity and humoral immune response, providing new ideas for the development of new coronavirus mRNA vaccines.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] In the first aspect of the present invention, the present invention provides an mRNA molecule, characterized in that the mRNA molecule comprises a natural sequence or a codon-optimized sequence encoding an antigen sequence, the antigen sequence comprises a plurality of novel coronavirus receptor binding domain (RBD) fragments and an immunoglobulin Fc fragment connected to the plurality of novel coronavirus RBD fragments, the plurality of novel coronavirus RBD fragments are composed of two, three, four or five different novel coronavirus RBD fragments connected in series; the novel coronavirus RBD fragment is selected from the RBD fragment itself or a mutant thereof; preferably, the novel coronavirus RBD fragment includes: RBD prototype, RBD beta, RBD delta and RBD BA.4.

[0008] Preferably, the novel coronavirus RBD fragments are connected by a linker;

[0009] Preferably, the linker is a GG or GS sequence;

[0010] Preferably, the linker is a GGS, GGGS, GSGS, SGGS, GGGGS, GSGGS, GGSGS, GGSGGS, GGGSGS, GGGGGS, GGGSGGS or GGGGSGGGGSGGGGSGT sequence.

[0011] Preferably, the C-termini of the multiple novel coronavirus receptor binding domain (RBD) fragments are connected to the immunoglobulin Fc fragment.

[0012] Preferably, the amino acid sequence of the novel coronavirus RBD fragment comprises the amino acid sequence shown in SEQ ID NO.1-SEQ ID NO.4 or its sequence derivative.

[0013] Preferably, the gene sequence encoding the novel coronavirus RBD fragment comprises the polynucleotide sequence shown in SEQ ID NO.5-SEQ ID NO.8 or its degenerate sequence.

[0014] In some embodiments, the connection between the multiple novel coronavirus RBD fragments and the immunoglobulin Fc fragment includes the following series patterns: RBD prototype-RBD beta-Fc; RBD delta-RBD BA.4-Fc; RBDBA.4-RBD delta-RBD prototype-Fc; RBD BA.4-RBD delta-RBD beta-RBD prototype-Fc.

[0015] Preferably, the immunoglobulin Fc fragment is derived from humans, mice, rabbits, cows, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs and other animals; preferably, the immunoglobulin Fc fragment is derived from the Fc fragment of human immunoglobulin;

[0016] Preferably, the immunoglobulin Fc fragment is an IgG Fc fragment, an IgA Fc fragment, an IgD Fc fragment, an IgE Fc fragment or an IgM Fc fragment;

[0017] Preferably, the IgG Fc fragment comprises an IgG1 Fc fragment, an IgG2 Fc fragment, an IgG3 Fc fragment, or an IgG4 Fc fragment.

[0018] Preferably, the Fc fragment of the human immunoglobulin includes further modification, and the modification includes YTE mutation or LS mutation, etc., and YTE mutation is preferably used.

[0019] Preferably, the amino acid sequence of the immunoglobulin Fc fragment comprises the amino acid sequence shown in SEQ ID NO.9 or SEQ ID NO.19 or a sequence derivative thereof.

[0020] Preferably, the gene sequence encoding the immunoglobulin Fc fragment comprises the polynucleotide sequence shown in SEQ ID NO.10 or SEQ ID NO.20 or a degenerate sequence thereof.

[0021] In some embodiments, the mRNA molecule comprises a sequence encoding an amino acid sequence shown in SEQ ID NO.11 to SEQ ID NO.14 or a sequence derivative thereof.

[0022] Preferably, the gene sequence encoding the mRNA molecule comprises the polynucleotide sequence shown in SEQ ID NO.15-SEQ ID NO.18 or a degenerate sequence thereof.

[0023] In some embodiments, the mRNA molecule further comprises one or more structural elements that are optimized for maximum efficacy of the mRNA in terms of stability and translation efficiency;

[0024] Preferably, the structural elements are 5' cap, 5' UTR, 3' UTR, poly (A)-tail;

[0025] More preferably, the mRNA comprises the 5' cap, 5' UTR, 3' UTR and poly (A) tail;

[0026] More preferably, the specific capping structure of the 5' cap is β-S-ARCA(D1)(m27,2"-OGppSpG) or m27,3'-OGppp(m12'-O)ApG; and / or

[0027] More preferably, the 5'-UTR is the 5'-UTR sequence of human α-globin or β-globin mRNA, and optionally has an optimized "Kozak" sequence to improve translation efficiency; and / or

[0028] More preferably, the 3'-UTR sequence is a combination of two sequence elements (FI element) derived from the "amino terminal enhancer of split" (AES) mRNA (called F) and the mitochondrial encoded 12S ribosomal RNA (called I) placed between the coding sequence and the poly (A)-tail in the aforementioned mRNA molecule to ensure higher maximum protein levels and prolonged mRNA persistence (see Nance KD, Meier J L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines [J]. ACS central science, 7 (5): 748-756.). These are identified by an in vitro selection process for sequences that confer RNA stability and increase total protein expression, or the 3'-UTR is preferably one or two repeated 3'-UTRs of human β-globin mRNA; and / or

[0029] More preferably, the poly(A)-tail is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 nucleotides in length; more preferably, the poly(A)-tail is 110 nucleotides in length, consisting of a stretch of 30 adenosine residues, followed by a 10 nucleotide linker sequence (random nucleotides) and another 70 adenosine residues. This poly(A)-tail sequence is designed to enhance RNA stability and translation efficiency.

[0030] In some embodiments, the mRNA molecule is a chemically modified mRNA molecule, and at least one chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiourea, 4′-thiourea, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyluridine.

[0031] In the second aspect of the present invention, the present invention provides an mRNA vaccine, characterized in that the mRNA vaccine comprises the mRNA molecule described in the first aspect of the present invention.

[0032] The third aspect of the present invention provides a method for preparing the mRNA vaccine described in the second aspect of the present invention, characterized in that the method comprises: encapsulating the mRNA molecule described in the first aspect into lipid nanoparticles (LNP).

[0033] The fourth aspect of the present invention provides a broad-spectrum novel coronavirus mRNA vaccine composition, characterized in that the mRNA vaccine composition contains at least two mRNA vaccines described in the second aspect of the present invention.

[0034] Preferably, the mRNA vaccine composition is formulated or is to be formulated as a liquid, a solid or a combination thereof;

[0035] In some embodiments, the mRNA vaccine composition is formulated or is to be formulated for injection;

[0036] Preferably, the mRNA vaccine composition is formulated or is to be formulated for intramuscular administration.

[0037] Preferably, the mRNA vaccine composition is an mRNA-lipid nanoparticle (LNP) vaccine composition;

[0038] More preferably, the LNP comprises ((4-hydroxybutyl)azadiyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine and cholesterol.

[0039] The fifth aspect of the present invention provides a method for preparing the mRNA-LNP vaccine composition according to the fourth aspect of the present invention, the method comprising any of the following steps:

[0040] (i) mixing at least two mRNA molecules according to the first aspect of the present invention and loading them into LNP; or

[0041] (ii) loading at least two mRNA molecules according to the first aspect of the present invention into LNPs and then mixing them.

[0042] In the sixth aspect of the present invention, the present invention provides the use of the mRNA molecule described in the first aspect of the present invention, the mRNA vaccine described in the second aspect, or the mRNA vaccine composition described in the fourth aspect in the preparation of a medicament for preventing / treating diseases caused by novel coronavirus infection.

[0043] Preferably, the medicament may further comprise one or more pharmaceutically acceptable carriers, diluents and / or excipients. DETAILED DESCRIPTION

[0044] It should be noted that, unless otherwise defined, the technical terms or scientific terms used in this application should have the common meanings understood by technicians in the relevant field.

[0045] The experimental methods in the following examples are conventional methods unless otherwise specified. The medicinal materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.

[0046] Herein, if the actual source is not specifically given, the reagent can be obtained from any supplier of molecular biology reagents in a quality / purity suitable for molecular biology applications.

[0047] definition

[0048] In the above and below, unless otherwise specified, the amino acid sequence derivative of the present invention is a sequence that is different from the natural amino acid sequence due to the deletion, insertion, non-conservative or conservative substitution or a combination thereof of one or more amino acid residues, and is a derivative with the same biological activity as the natural amino acid sequence or improved structural stability (such as heat resistance, pH resistance, etc.).

[0049] In the above and below, the amino acid sequence derivatives of the present invention have a sequence identity with the native amino acid sequence of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.

[0050] In the above and below, the Fc of the present invention is an IgG (IgG1, IgG2, IgG3, IgG4), IgA (IgA1, IgA2), IgD, IgE or IgM isotype Fc.

[0051] In the above and below, the “YTE mutation” of the present invention refers to that the Fc comprises the following amino acids at the specified positions (EU index number): tyrosine at position 252, threonine at position 254 and glutamic acid at position 256.

[0052] In the above and below, the “LS mutation” described in the present invention means that the Fc region comprises the following amino acids at the specified positions (EU index number): Leucine at position 428 and Serine at position 434.

[0053] Example 1: Plasmid template linearization

[0054] Table 1. BspQI restriction enzyme digestion plasmid system

[0055] 10X NEBuffer (provided with BspQI enzyme) 100μL pVAX1 Plasmid 20μL QUR 20μL Nuclease-free Water(Invitrogen) 860μL

[0056] The pVAX1 plasmid was synthesized from GenScript Bioplasma, and the pVAX1 plasmid carries a HindIII / SpeI multiple cloning site and SEQ ID NO.15-18 sequences inserted through the multiple cloning site.

[0057] The reaction was incubated at 50°C for 1 hour and terminated by incubation at 80°C for 20 minutes.

[0058] The plasmid was precipitated using the Dr.GenTLE Precipitation Carrier kit (takara). Add 75 μL of 3M Sodium Acetate (pH 5.2, self-prepared) to each tube of the digested product; add 8 μL of Dr.GenTLE Precipitation Carrier respectively and mix well; add 20 mL of anhydrous ethanol, mix, and ice bath at -20°C for 30 min; centrifuge at 4°C, 12000 rpm for 30 min, and remove the supernatant; add 10 mL of 70% ethanol and gently tap the bottom of the tube; centrifuge at 4°C, 12000 rpm for 5 min, and remove the supernatant; dry the precipitate, add 200 μL of Nuclease-free Water, dissolve the precipitate, mix well and store at -20°C for later use.

[0059] Example 2: In vitro transcription of mRNA The materials were added according to the system in Table 2 to carry out in vitro transcription reaction, and two tubes of 1 mL system were reacted in duplicate.

[0060] Table 2. mRNA in vitro transcription system

[0061]

[0062]

[0063] The commercially available reagents in this table were purchased from Novazonics.

[0064] After mixing, the mixture was reacted at 37°C for 2 hours, and 50 μL of DNase I was added and reacted for 15 minutes to obtain crude in vitro transcribed mRNA.

[0065] Example 3: mRNA purification

[0066] The crude in vitro transcribed mRNA obtained in Example 2 was purified using RNeasy midi Kit (Qiagen).

[0067] Preparation of Buffer RLT: Before use, add 10 μL of β-mercaptoethanol per 1 mL of Buffer RLT according to the kit instructions.

[0068] Preparation of Buffer RPE: Before use, add 4 times the volume of ethanol (96-100%) according to the instructions of the kit to prepare the working solution.

[0069] Adjust the crude product of in vitro transcribed mRNA obtained in Example 2 to 166 μL with RNase-free water, add 4 mL Buffer RLT, and mix thoroughly. Add 2.8 mL ethanol (96-100%) and mix thoroughly. After adding the mixture to the RNeasy Midicolumn, place it in a 15 mL centrifuge tube and centrifuge at 4000 × g for 5 minutes. Discard the liquid that flows through. Add 2.5 mL Buffer RPE to the RNeasy Midi column again, centrifuge at 4000 × g for 2 minutes to wash the column, and discard the flow-through liquid. Add another 2.5 mL Buffer RPE to the centrifuge column and centrifuge at 5000 × g for 5 minutes. Transfer the RNeasy column to a new 15 ml collection tube and add 250 μL of RNase-free water directly to the RNeasy silica membrane. After standing for 60 minutes, centrifuge at 5000 × g for 3 minutes to elute. Repeat the elution once with the eluent from the previous step. The mixture was eluted for the second time with 150 μL of new RNase-free water, allowed to stand at room temperature for 20 min, and then centrifuged at 5000×g for 6 min to obtain the purified mRNA in vitro transcription product.

[0070] Example 4: Enzymatic capping of mRNA

[0071] mRNA denaturation: The purified mRNA in Example 3 was heated at 65°C for 10 min and placed in an ice bath for 10 min.

[0072] Use Cap 1 Capping System to cap the denatured mRNA and prepare the capping reaction system according to Table 3.

[0073] Table 3. Capping reaction system

[0074]

[0075]

[0076] The commercially available reagents in this table were purchased from Novazonics.

[0077] Incubate in a water bath at 37°C for 2 h.

[0078] Purify the capped mRNA: Use RNeasy midi Kit (Qiagen) to purify the system after the reaction. The purification steps are the same as those in Example 3 for purifying the crude in vitro transcribed mRNA obtained in Example 2, and set aside.

[0079] Example 5: Preparation of mRNA lipid nanoparticles (LNP)

[0080] 1. Oil-water phase preparation:

[0081] ALC-0315 (Xiamen Sinobond), ALC-0159 (Xiamen Sinobond), cholesterol and distearoylphosphatidylcholine (DSPC) were weighed according to the prescription amount corresponding to the molar percentage of the following components, dissolved in anhydrous ethanol to obtain an oil phase, and filtered with a 0.45 μm microporous filter membrane for use. The prepared total lipid concentration was 36.4 mM, and the molar percentages of ALC-0315, ALC-0159, cholesterol and DSPC were 46.3%:1.6%:42.7%:9.4%.

[0082] The mRNA stock solution was diluted with 50 mM enzyme-free citric acid buffer (commercially available product) to obtain an aqueous phase. The mRNA stock solution was the purified capped mRNA obtained in Example 4. The microfluidic mixing parameters were calculated based on the relative molecular weight of each base being 330 and the N / P ratio being 6:1.

[0083] 2. Microfluidic Mixing

[0084] The oil phase and the aqueous phase were mixed using a microfluidic device, the oil phase flow rate was set to 8 mL / min, and the aqueous phase flow rate was set to 24 mL / min. The mixed liquid was collected, and the ethanol was removed by static dialysis for 24 h and replaced with DPBS. Finally, the lipid nanoparticles were filtered through a 0.2 μm sterile filter to obtain the encapsulated LNP preparation.

[0085] 3. Ultrafiltration and Filtration

[0086] The feed solution was concentrated with an ultrafiltration tube to a final mRNA concentration of 0.5 mg / mL, and replaced with a 12 mM PBS buffer containing 10% sucrose, and finally filtered with a 0.22 μm microporous filter membrane to obtain the final sample. The sample was stored in a -80°C refrigerator for later use.

[0087] Example 6: Vaccine Immunization

[0088] The final sample obtained in Example 5 was administered by intramuscular injection into the hind legs of female BALB / c mice. The dosage was as shown in Table 6. The grouping and immunization schedule were as shown in Table 6. There were 10 mice in each group.

[0089] Blood collection method: Blood was collected from the eyeball and placed in a 1.5 ml sterile EP tube. The tube was placed at room temperature for 2 hours and centrifuged at 13,000 rpm for 10 minutes to separate the serum. The blood was then divided and stored below -20°C.

[0090] Table 6: Grouping and immunization schedule:

[0091]

[0092] Example 7: Neutralizing Antibody Activity Detection

[0093] Neutralizing antibody detection (pseudovirus system) was commissioned to Novazonics. The experimental material provided to Novazonics was the mouse serum obtained in Example 8, and the pseudovirus and its detection were provided by Novazonics.

[0094] The results are shown in Table 7. The mRNA vaccine and its composition provided by the present invention have neutralizing activity against a variety of mutants. These results show that the mRNA vaccine and its composition of the present invention can induce a wide range of broad-spectrum neutralizing activity, providing a new strategy for combating strain mutations and improving the effectiveness of vaccines.

[0095] Table 7:

[0096]

[0097] Example 8: Immunological persistence

[0098] The final sample obtained in Example 5 was administered by intramuscular injection into the hind legs of female BALB / c mice. The dosage was as shown in Table 8. The grouping and immunization schedule were as shown in Table 5. There were 10 mice in each group.

[0099] Blood collection method: Blood was collected from the eyeball and placed in a 1.5 ml sterile EP tube. The tube was placed at room temperature for 2 hours and centrifuged at 13,000 rpm for 10 minutes to separate the serum. The blood was then divided and stored below -20°C.

[0100] Table 8: Grouping and immunization schedule:

[0101]

[0102] Example 9: Neutralizing antibody immune persistence detection

[0103] Neutralizing antibody detection (pseudovirus system) was commissioned to Novazonics. The experimental material provided to Novazonics was the mouse serum obtained in Example 8, and the pseudovirus and its detection were provided by Novazonics.

[0104] Table 9:

[0105]

[0106] The results showed that 70 days after the second immunization (refer to row D91 in Table 9), the neutralizing antibodies against each new coronavirus still remained at a high level, indicating that the vaccine has good persistent immunogenicity.

[0107] SEQ ID NO.1prototype

[0108] RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL

[0109] YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIAD

[0110] YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEI

[0111] YQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPAT

[0112] VCGPKKSTNLVKNK

[0113] SEQ ID NO.2 beta

[0114] RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL

[0115] YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIAD

[0116] YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEI

[0117] YQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPAT

[0118] VCGPKKSTNLVKNK

[0119] SEQ ID NO.3 delta

[0120] RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL

[0121] YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIAD

[0122] YNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEI

[0123] YQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPAT

[0124] VCGPKKSTNLVKNK

[0125] SEQ ID NO.4 BA.4

[0126] RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVL

[0127] YNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIAD

[0128] YNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEI

[0129] YQAGNKPCNGVAGVNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHAPA

[0130] TVCGPKKSTNLVKNK

[0131] SEQ ID NO.5 prototype

[0132] CGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAA

[0133] TCTGTGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGT

[0134] ACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGT

[0135] GCTGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCC

[0136] CTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTT

[0137] CGTGATCCGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGC

[0138] AAGATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGTG

[0139] TGATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTA

[0140] CAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGC

[0141] GGGACATCTCCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAACGG

[0142] CGTGGAAGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGC

[0143] CCACAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTT

[0144] CGAACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACC

[0145] AATCTCGTGAAGAACAAA

[0146] SEQ ID NO.6 beta

[0147] CGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAA

[0148] TCTGTGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGT

[0149] ACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGT

[0150] GCTGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCC

[0151] CTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTT

[0152] CGTGATCCGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGC

[0153] AACATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGTG

[0154] TGATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTA

[0155] CAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGC

[0156] GGGACATCTCCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAACGG

[0157] CGTGAAGGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGC

[0158] CCACATACGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTT

[0159] CGAACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACC

[0160] AATCTCGTGAAGAACAAA

[0161] SEQ ID NO.7 delta

[0162] CGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAA

[0163] TCTGTGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGT

[0164] ACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGT

[0165] GCTGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCC

[0166] CTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTT

[0167] CGTGATCCGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGC

[0168] AAGATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGTG

[0169] TGATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTA

[0170] CAATTACCGCTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGC

[0171] GGGACATCTCCACCGAGATCTATCAGGCCGGCAGCAAGCCTTGTAACGG

[0172] CGTGGAAGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGC

[0173] CCACAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTT

[0174] CGAACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACC

[0175] AATCTCGTGAAGAACAAA

[0176] SEQ ID NO.8 BA.4

[0177] CGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAA

[0178] TCTGTGCCCCTTCGACGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGT

[0179] ACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGT

[0180] GCTGTACAACTTCGCCCCCTTCTTCGCGTTCAAGTGCTACGGCGTGTCCC

[0181] CTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTT

[0182] CGTGATCCGGGGAAACGAAGTGAGCCAGATTGCCCCTGGACAGACAGGC

[0183] AACATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGTG

[0184] TGATTGCCTGGAACAGCAACAAGCTGGACTCCAAAGTCGGCGGCAACTA

[0185] CAATTACCGCTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGC

[0186] GGGACATCTCCACCGAGATCTATCAGGCCGGCAACAAGCCTTGTAACGG

[0187] CGTGGCCGGCGTCAACTGCTACTTCCCACTGCGCTCCTACGGCTTTCGCC

[0188] CCACATACGGCGTGGGCCACCAGCCCTACAGAGTGGTGGTGCTGAGCTT

[0189] CGAACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACC

[0190] AATCTCGTGAAGAACAAA

[0191] SEQ ID NO.9

[0192] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD

[0193] VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL

[0194] NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT

[0195] CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW

[0196] QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0197] SEQ ID NO.10

[0198] GAGCCCAAGAGTTGTGACAAGACTCATACGTGTCCTCCGTGCCCGGC

[0199] CCCCGAGCTCCTCGGTGGACCGTCAGTCTTCCTGTTCCCACCGAAGCCAA

[0200] AGGACACACTCATGATCTCAAGGACGCCGGAGGTAACCTGTGTCGTAGT

[0201] AGATGTCAGCCATGAGGATCCAGAGGTAAAGTTCAACTGGTATGTGGAC

[0202] GGAGTTGAGGTACATAACGCCAAGACGAAGCCGCGCGAGGAGCAGTAC

[0203] AACAGCACGTACAGGGTAGTGTCTGTACTGACGGTACTCCATCAGGATT

[0204] GGCTCAACGGCAAGGAGTACAAGTGTAAGGTCTCTAACAAGGCCCTGCC

[0205] TGCGCCCATCGAGAAGACCATCTCTAAGGCCAAGGGGCAGCCGAGAGAG

[0206] CCCCAGGTATATACTCTCCCCCCATCACGCGACGAGTTGACTAAGAACC

[0207] AGGTCTCTTTGACTTGTCTGGTGAAGGGGTTCTACCCCTCAGACATCGCA

[0208] GTCGAGTGGGAGTCTAACGGGCAGCCGGAGAACAACTATAAGACAACCC

[0209] CCCCGGTCCTCGACTCTGACGGGTCATTCTTCTTGTACTCTAAGCTCACA

[0210] GTAGACAAGTCTCGATGGCAGCAGGGGAACGTCTTCTCCTGCTCAGTGA

[0211] TGCATGAGGCGTTGCACAACCACTATACACAGAAGAGTCTGTCTCTCTCA

[0212] CCTGGCAAGTGATGA

[0213] SEQ ID NO.11

[0214] MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNR

[0215] KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEV

[0216] RQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRK

[0217] SNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV

[0218] VVLSFELLHAPATVCGPKKSTNLVKNKGGGGSRVQPTESIVRFPNITNLCPF

[0219] GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND

[0220] LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNN

[0221] LDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPL

[0222] QSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKGGGGS

[0223] GGGGSGGGGSGTEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT

[0224] PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL

[0225] TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL

[0226] TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL

[0227] TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0228] SEQ ID NO.12

[0229] MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNR

[0230] KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEV

[0231] RQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFR

[0232] KSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYR

[0233] VVVLSFELLHAPATVCGPKKSTNLVKNKGGGGSRVQPTESIVRFPNITNLCP

[0234] FDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLN

[0235] DLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN

[0236] KLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGVNCYF

[0237] PLRSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKGGGG

[0238] SGGGGSGGGGSGTEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITR

[0239] EPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV

[0240] LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE

[0241] LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK

[0242] LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0243] SEQ ID NO.13

[0244] MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRI

[0245] SNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQI

[0246] APGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSN

[0247] LKPFERDISTEIYQAGNKPCNGVAGVNCYFPLRSYGFRPTYGVGHQPYRVV

[0248] VLSFELLHAPATVCGPKKSTNLVKNKGGGGSRVQPTESIVRFPNITNLCPFGE

[0249] VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC

[0250] FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD

[0251] SKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQS

[0252] YGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKGGGGS

[0253] RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYN

[0254] SASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYN

[0255] YKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQ

[0256] AGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVC

[0257] GPKKSTNLVKNKGGGGSGGGGSGGGGSGTEPKSCDKTHTCPPCPAPELLGG

[0258] PSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK

[0259] TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA

[0260] KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

[0261] YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL

[0262] SLSPGK

[0263] SEQ ID NO.14

[0264] MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRI

[0265] SNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQI

[0266] APGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSN

[0267] LKPFERDISTEIYQAGNKPCNGVAGVNCYFPLRSYGFRPTYGVGHQPYRVV

[0268] VLSFELLHAPATVCGPKKSTNLVKNKGGGGSRVQPTESIVRFPNITNLCPFGE

[0269] VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC

[0270] FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD

[0271] SKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQS

[0272] YGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKGGGGSRV

[0273] QPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSA

[0274] SFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYK

[0275] LPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG

[0276] STPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGP

[0277] KKSTNLVKNKGGGGSRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNR

[0278] KRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEV

[0279] RQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRK

[0280] SNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV

[0281] VVLSFELLHAPATVCGPKKSTNLVKNKGGGGSGGGGSGGGGSGTEPKSCD

[0282] KTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVK

[0283] FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV

[0284] SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD

[0285] IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV

[0286] MHEALHNHYTQKSLSLSPGK

[0287] SEQ ID NO.15

[0288] GGACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACCGCCACCAT

[0289] GTTCGTGTTCTTGGTCCTCCTCCCTTTGGTATCCTCACGGGTGCAGCCCAC

[0290] CGAATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCTTCGGCG

[0291] AGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAA

[0292] GCGGATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTCCGCC

[0293] AGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACG

[0294] ACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGA

[0295] TGAAGTGCGGCAGATTGCCCCTGGACAGACAGGCAAGATCGCCGACTAC

[0296] AACTACAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAACA

[0297] GCAACAACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCG

[0298] GCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACC

[0299] GAGATCTATCAGGCCGGCAGCACCCCTTGTAACGGCGTGGAAGGCTTCA

[0300] ACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGCCCACAAATGGCGTG

[0301] GGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATG

[0302] CCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATCTCGTGAAGAA

[0303] CAAAGGAGGGGGCGGAAGCCGGGTGCAGCCCACCGAATCCATCGTGCG

[0304] GTTCCCCAATATCACCAATCTGTGCCCCTTCGGCGAGGTGTTCAATGCCA

[0305] CCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTG

[0306] CGTGGCCGACTACTCCGTGCTGTACAACTCCGCCAGCTTCAGCACCTTCA

[0307] AGTGCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCACAAA

[0308] CGTGTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATT

[0309] GCCCCTGGACAGACAGGCAACATCGCCGACTACAACTACAAGCTGCCCG

[0310] ACGACTTCACCGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACTC

[0311] CAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCC

[0312] AATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCG

[0313] GCAGCACCCCTTGTAACGGCGTGAAGGGCTTCAACTGCTACTTCCCACTG

[0314] CAGTCCTACGGCTTTCAGCCCACATACGGCGTGGGCTATCAGCCCTACAG

[0315] AGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTGCCACAGTGTGCG

[0316] GCCCTAAGAAAAGCACCAATCTCGTGAAGAACAAAGGGGGTGGAGGAT

[0317] CTGGCGGTGGCGGTAGTGGTGGCGGAGGGAGCGGAACAGAGCCCAAGA

[0318] GTTGTGACAAGACTCATACGTGTCCTCCGTGCCCGGCCCCCGAGCTCCTC

[0319] GGTGGACCGTCAGTCTTCCTGTTCCCACCGAAGCCAAAGGACACACTCA

[0320] TGATCTCAAGGACGCCGGAGGTAACCTGTGTCGTAGTAGATGTCAGCCA

[0321] TGAGGATCCAGAGGTAAAGTTCAACTGGTATGTGGACGGAGTTGAGGTA

[0322] CATAACGCCAAGACGAAGCCGCGCGAGGAGCAGTACAACAGCACGTAC

[0323] AGGGTAGTGTCTGTACTGACGGTACTCCATCAGGATTGGCTCAACGGCA

[0324] AGGAGTACAAGTGTAAGGTCTCTAACAAGGCCCTGCCTGCGCCCATCGA

[0325] GAAGACCATCTCTAAGGCCAAGGGGCAGCCGAGAGAGCCCCAGGTATAT

[0326] ACTCTCCCCCCATCACGCGACGAGTTGACTAAGAACAGGTCTCTTTGAC

[0327] TTGTCTGGTGAAGGGGTTCTACCCCTCAGACATCGCAGTCGAGTGGGAG

[0328] TCTAACGGGCAGCCGGAGAACAACTATAAGACAACCCCCCCGGTCCTCG

[0329] ACTCTGACGGGTCATTCTTCTTGTACTCTAAGCTCACAGTAGACAAGTCT

[0330] CGATGGCAGCAGGGGAACGTCTTCTCCTGCTCAGTGATGCATGAGGCGT

[0331] TGCACAACCACTATACACAGAAGAGTCTGTCTCTCTCACCCTGGCAAGTG

[0332] ATGAGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCC

[0333] AGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAG

[0334] TCTGAGTGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAT

[0335] ATGACTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0336] AAAAAAAAAAAAAAAAAAAAAAAAAAA

[0337] SEQ ID NO.16

[0338] GGACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACCGCCACCAT

[0339] GTTCGTGTTCTTGGTCCTCCTCCCTTTGGTATCCTCACGGGTGCAGCCCAC

[0340] CGAATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCTTCGGCG

[0341] AGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAA

[0342] GCGGATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTCCGCC

[0343] AGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACG

[0344] ACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGA

[0345] TGAAGTGCGGCAGATTGCCCCTGGACAGACAGGCAAGATCGCCGACTAC

[0346] AACTACAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAACA

[0347] GCAACAACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCGCTACCG

[0348] GCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACC

[0349] GAGATCTATCAGGCCGGCAGCAAGCCTTGTAACGGCGTGGAAGGCTTCA

[0350] ACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGCCCACAAATGGCGTG

[0351] GGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATG

[0352] CCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATCTCGTGAAGAA

[0353] CAAAGGAGGGGGCGGAAGCCGGGTGCAGCCCACCGAATCCATCGTGCG

[0354] GTTCCCCAATATCACCAATCTGTGCCCCTTCGACGAGGTGTTCAATGCCA

[0355] CCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTG

[0356] CGTGGCCGACTACTCCGTGCTGTACAACTTCGCCCCCTTCTTCGCGTTCA

[0357] AGTGCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCACAAA

[0358] CGTGTACGCCGACAGCTTCGTGATCCGGGGAAACGAAGTGAGCCAGATT

[0359] GCCCCTGGACAGACAGGCAACATCGCCGACTACAACTACAAGCTGCCCG

[0360] ACGACTTCACCGGCTGTGTGATTGCCTGGAACAGCAACAAGCTGGACTC

[0361] CAAAGTCGGCGGCAACTACAATTACCGCTACCGGCTGTTCCGGAAGTCC

[0362] AATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCG

[0363] GCAACAAGCCTTGTAACGGCGTGGCCGGCGTCAACTGCTACTTCCCACT

[0364] GCGCTCCTACGGCTTTCGCCCCACATACGGCGTGGGCCACCAGCCCTACA

[0365] GAGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTGCCACAGTGTGC

[0366] GGCCCTAAGAAAAGCACCAATCTCGTGAAGAACAAAGGGGGTGGAGGA

[0367] TCTGGCGGTGGCGGTAGTGGTGGCGGAGGGAGCGGAACAGAGCCCAAG

[0368] AGTTGTGACAAGACTCATACGTGTCCTCCGTGCCCGGCCCCCGAGCTCCT

[0369] CGGTGGACCGTCAGTCTTCCTGTTCCCACCGAAGCCAAAGGACACACTCT

[0370] ACATCACGAGGGAGCCGGAGGTAACCTGTGTCGTAGTAGATGTCAGCCA

[0371] TGAGGATCCAGAGGTAAAGTTCAACTGGTATGTGGACGGAGTTGAGGTA

[0372] CATAACGCCAAGACGAAGCCGCGCGAGGAGCAGTACAACAGCACGTAC

[0373] AGGGTAGTGTCTGTACTGACGGTACTCCATCAGGATTGGCTCAACGGCA

[0374] AGGAGTACAAGTGTAAGGTCTCTAACAAGGCCCTGCCTGCGCCCATCGA

[0375] GAAGACCATCTCTAAGGCCAAGGGGCAGCCGAGAGAGCCCCAGGTATAT

[0376] ACTCTCCCCCCATCACGCGACGAGTTGACTAAGAACCAGGTCTCTTTGAC

[0377] TTGTCTGGTGAAGGGGTTCTACCCCTCAGACATCGCAGTCGAGTGGGAG

[0378] TCTAACGGGCAGCCGGAGAACAACTATAAGACAACCCCCCCGGTCCTCG

[0379] ACTCTGACGGGTCATTCTTCTTGTACTCTAAGCTCACAGTAGACAAGTCT

[0380] CGATGGCAGCAGGGGAACGTCTTCTCCTGCTCAGTGATGCATGAGGCGT

[0381] TGCACAACCACTATACACAGAAGAGTCTGTCTCTCTCACCTGGCAAGTG

[0382] ATGAGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCC

[0383] AGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAG

[0384] TCTGAGTGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAT

[0385] ATGACTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0386] AAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0387] SEQ ID NO.17

[0388] GGACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACCGCCACCAT

[0389] GTTCGTGTTCTTGGTCCTCCTCCCTTTGGTATCCTCACGGGTGCAGCCCAC

[0390] CGAATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCTTCGACG

[0391] AGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAA

[0392] GCGGATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTTCGCCC

[0393] CCTTCTTCGCGTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACGAC

[0394] CTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAAACG

[0395] AAGTGAGCCAGATTGCCCCTGGACAGACAGAGGGCAACATCGCCGACTACAA

[0396] CTACAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAACAGC

[0397] AACAAGCTGGACTCCAAAGTCGGCGGCAACTACATTACCGCTACCGGC

[0398] TGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGGACATCTCCACCGA

[0399] GATCTATCAGGCCGGCAACAAGCCTTGTAACGGCGTGGCCGGCTTCAAC

[0400] TGCTACTTCCCACTGCGCTCCTACGGCTTTCGCCCCACATACGGCGTGGG

[0401] CCACCAGCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCC

[0402] CCTGCCACAGTGTGCGGCCCTAAGAAAGCACCAATCTCGTGAAGAACA

[0403] AAGGAGGGGGGCGGAAGCCGGGTGCAGCCCACCGAATCCATCGTGCGGTT

[0404] CCCCAATATCACCAATCTGTGCCCCTTCGGCGAGGTGTTCAATGCCACCA

[0405] GATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTGCGT

[0406] GGCCGACTACTCCGTGCTGTACAACTCCGCCAGCTTCAGCACCTTCCAAGT

[0407] GCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCACAAACGT

[0408] GTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATTGCC

[0409] CCTGGACAGACAGGCAAGATCGCCGACTACACTACAAGCTGCCCGACG

[0410] ACTTCACCGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACTCCAA

[0411] AGTCGGCGCAACTACAATTACCGCTACCGGCTGTTCCGGAAGTCCAAT

[0412] CTGAAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCGGCA

[0413] GCAAGCCTTGTAACGGCGTGGAAGGCTTCAACTGCTACTTCCCACTGCA

[0414] GTCCTACGGCTTTCAGCCCACAAATGGCGTGGGCTATCAGCCCTACAGA

[0415] GTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTGCCACAGTGTGCGG

[0416] CCCTAAGAAAAGCACCAATCTCGTGAAGAACAAAGGAGGGGGCGGGAAG

[0417] CCGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAATC

[0418] TGTGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGTAC

[0419] GCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGTGC

[0420] TGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCT

[0421] ACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCG

[0422] TGATCCGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGCAA

[0423] GATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGTGTG

[0424] ATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTACA

[0425] ATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGG

[0426] GACATCTCCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAACGGCG

[0427] TGGAAGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGCCC

[0428] ACAAATGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCG

[0429] AACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAA

[0430] TCTCGTGAAGAACAAAGGGGGTGGAGGATCTGGCGGTGGCGGTAGTGGT

[0431] GGCGGAGGGAGCGGAACAGAGCCCAAGAGTTGTGACAAGACTCATACG

[0432] TGTCCTCCGTGCCCGGCCCCCGAGCTCCTCGGTGGACCGTCAGTCTTCCT

[0433] GTTCCCACCGAAGCCAAAGGACACACTCTACATCACGAGGGAGCCGGAG

[0434] GTAACCTGTGTCGTAGTAGATGTCAGCCATGAGGATCCAGAGGTAAAGT

[0435] TCAACTGGTATGTGGACGGAGTTGAGGTACATAACGCCAAGACGAAGCC

[0436] GCGCGAGGAGCAGTACAACAGCACGTACAGGGTAGTGTCTGTACTGACG

[0437] GTACTCCATCAGGATTGGCTCAACGGCAAGGAGTACAAGTGTAAGGTCT

[0438] CTAACAAGGCCCTGCCTGCGCCCATCGAGAAGACCATCTCTAAGGCCAA

[0439] GGGGCAGCCGAGAGAGCCCCAGGTATATACTCTCCCCCCATCACGCGAC

[0440] GAGTTGACTAAGAACCAGGTCTCTTTGACTTGTCTGGTGAAGGGGTTCTA

[0441] CCCCTCAGACATCGCAGTCGAGTGGGAGTCTAACGGGCAGCCGGAGAAC

[0442] AACTATAAGACAACCCCCCCGGTCCTCGACTCTGACGGGTCATTCTTCTT

[0443] GTACTCTAAGCTCACAGTAGACAAGTCTCGATGGCAGCAGGGGAACGTC

[0444] TTCTCCTGCTCAGTGATGCATGAGGCGTTGCACAACCACTATACACAGAA

[0445] GAGTCTGTCTCTCTCACCTGGCAAGTGATGAGCTGGAGCCTCGGTGGCCA

[0446] TGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACC

[0447] CGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCAAAAAAAAA

[0448] AAAAAAAAAAAAAAAAAAAAAGCATATGACTAAAAAAAAAAAAAAAA

[0449] AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0450] AAAAAAA

[0451] SEQ ID NO.18

[0452] GGACTCTTCTGGTCCCCACAGACTCAGAGAGAACCCACCGCCACCAT

[0453] GTTCGTGTTCTTGGTCCTCCTCCCTTTGGTATCCTCACGGGTGCAGCCCAC

[0454] CGAATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCTTCGACG

[0455] AGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAA

[0456] GCGGATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTTCGCCC

[0457] CCTTCTTCGCGTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACGAC

[0458] CTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAAACG

[0459] AAGTGAGCCAGATTGCCCCTGGACAGACAGAGGGCAACATCGCCGACTACAA

[0460] CTACAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAACAGC

[0461] AACAAGCTGGACTCCAAAGTCGGCGGCAACTACATTACCGCTACCGGC

[0462] TGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGGACATCTCCACCGA

[0463] GATCTATCAGGCCGGCAACAAGCCTTGTAACGGCGTGGCCGGCTTCAAC

[0464] TGCTACTTCCCACTGCGCTCCTACGGCTTTCGCCCCACATACGGCGTGGG

[0465] CCACCAGCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCC

[0466] CCTGCCACAGTGTGCGGCCCTAAGAAAGCACCAATCTCGTGAAGAACA

[0467] AAGGAGGGGGGCGGAAGCCGGGTGCAGCCCACCGAATCCATCGTGCGGTT

[0468] CCCCAATATCACCAATCTGTGCCCCTTCGGCGAGGTGTTCAATGCCACCA

[0469] GATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTGCGT

[0470] GGCCGACTACTCCGTGCTGTACAACTCCGCCAGCTTCAGCACCTTCCAAGT

[0471] GCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCACAAACGT

[0472] GTACGCCGACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATTGCC

[0473] CCTGGACAGACAGGCAAGATCGCCGACTACACTACAAGCTGCCCGACG

[0474] ACTTCACCGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACTCCAA

[0475] AGTCGGCGCAACTACAATTACCGCTACCGGCTGTTCCGGAAGTCCAAT

[0476] CTGAAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCGGCA

[0477] GCAAGCCTTGTAACGGCGTGGAAGGCTTCAACTGCTACTTCCCACTGCA

[0478] GTCCTACGGCTTTCAGCCCACAAATGGCGTGGGCTATCAGCCCTACAGA

[0479] GTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTGCCACAGTGTGCGG

[0480] CCCTAAGAAAAGCACCAATCTCGTGAAGAACAAAGGAGGGGGCGGGAAG

[0481] CCGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAATC

[0482] TGTGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGTAC

[0483] GCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGTGC

[0484] TGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCT

[0485] ACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCG

[0486] TGATCCGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGCAA

[0487] CATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCTGTGTG

[0488] ATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGCGGCAACTACA

[0489] ATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTGAAGCCCTTCGAGCGG

[0490] GACATCTCCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAACGGCG

[0491] TGAAGGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGCCC

[0492] ACATACGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCG

[0493] AACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAA

[0494] TCTCGTGAAGAACAAAGGAGGGGGCGGAAGCCGGGTGCAGCCCACCGA

[0495] ATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCTTCGGCGAGG

[0496] TGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCG

[0497] GATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTCCGCCAGCT

[0498] TCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACGACCTG

[0499] TGCTTCACAAACGTGTACGCCGACAGCTTCGTGATCCGGGGAGATGAAG

[0500] TGCGGCAGATTGCCCCTGGACAGACAGGCAAGATCGCCGACTACAACTA

[0501] CAAGCTGCCCGACGACTTCACCGGCTGTGTGATTGCCTGGAACAGCAAC

[0502] AACCTGGACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGT

[0503] TCCGGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAGAT

[0504] CTATCAGGCCGGCAGCACCCCTTGTAACGGCGTGGAAGGCTTCAACTGC

[0505] TACTTCCCACTGCAGTCCTACGGCTTTCAGCCCACAAATGGCGTGGGCTA

[0506] TCAGCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTG

[0507] CCACAGTGTGCGGCCCTAAGAAAAGCACCAATCTCGTGAAGAACAAAGG

[0508] GGGTGGAGGATCTGGCGGTGGCGGTAGTGGTGGCGGAGGGAGCGGAAC

[0509] AGAGCCCAAGAGTTGTGACAAGACTCATACGTGTCCTCCGTGCCCGGCC

[0510] CCCGAGCTCCTCGGTGGACCGTCAGTCTTCCTGTTCCCACCGAAGCCAAA

[0511] GGACACACTCTACATCACGAGGGAGCCGGAGGTAACCTGTGTCGTAGTA

[0512] GATGTCAGCCATGAGGATCCAGAGGTAAAGTTCAACTGGTATGTGGACG

[0513] GAGTTGAGGTACATAACGCCAAGACGAAGCCGCGCGAGGAGCAGTACA

[0514] ACAGCACGTACAGGGTAGTGTCTGTACTGACGGTACTCCATCAGGATTG

[0515] GCTCAACGGCAAGGAGTACAAGTGTAAGGTCTCTAACAAGGCCCTGCCT

[0516] GCGCCCATCGAGAAGACCATCTCTAAGGCCAAGGGGCAGCCGAGAGAG

[0517] CCCCAGGTATATACTCTCCCCCCATCACGCGACGAGTTGACTAAGAACC

[0518] AGGTCTCTTTGACTTGTCTGGTGAAGGGGTTCTACCCCTCAGACATCGCA

[0519] GTCGAGTGGGAGTCTAACGGGCAGCCGGAGAACAACTATAAGACAACCC

[0520] CCCCGGTCCTCGACTCTGACGGGTCATTCTTCTTGTACTCTAAGCTCACA

[0521] GTAGACAAGTCTCGATGGCAGCAGGGGAACGTCTTCTCCTGCTCAGTGA

[0522] TGCATGAGGCGTTGCACAACCACTATACACAGAAGAGTCTGTCTCTCTCA

[0523] CCTGGCAAGTGATGAGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTG

[0524] GGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTC

[0525] TTTGAATAAAGTCTGAGTGGGCGGCAAAAAAAAAAAAAAAAAAAAAAA

[0526] AAAAAAAGCATATGACTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0527] AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0528] SEQ ID NO.19

[0529] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDV

[0530] SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN

[0531] GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC

[0532] LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ

[0533] QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0534] SEQ ID NO.20

[0535] GAGCCCAAGAGTTGTGACAAGACTCATACGTGTCCTCCGTGCCCGGC

[0536] CCCCGAGCTCCTCGGTGGACCGTCAGTCTTCCTGTTCCCACCGAAGCCAA

[0537] AGGACACACTCTACATCACGAGGGAGCCGGAGGTAACCTGTGTCGTAGT

[0538] AGATGTCAGCCATGAGGATCCAGAGGTAAAGTTCAACTGGTATGTGGAC

[0539] GGAGTTGAGGTACATAACGCCAAGACGAAGCCGCGCGAGGAGCAGTAC

[0540] AACAGCACGTACAGGGTAGTGTCTGTACTGACGGTACTCCATCAGGATT

[0541] GGCTCAACGGCAAGGAGTACAAGTGTAAGGTCTCTAACAAGGCCCTGCC

[0542] TGCGCCCATCGAGAAGACCATCTCTAAGGCCAAGGGGCAGCCGAGAGAG

[0543] CCCCAGGTATATACTCTCCCCCCATCACGCGACGAGTTGACTAAGAACC

[0544] AGGTCTCTTTGACTTGTCTGGTGAAGGGGTTCTACCCCTCAGACATCGCA

[0545] GTCGAGTGGGAGTCTAACGGGCAGCCGGAGAACAACTATAAGACAACCC

[0546] CCCCGGTCCTCGACTCTGACGGGTCATTCTTCTTGTACTCTAAGCTCACA

[0547] GTAGACAAGTCTCGATGGCAGCAGGGGAACGTCTTCTCCTGCTCAGTGA

[0548] TGCATGAGGCGTTGCACAACCACTATACACAGAAGAGTCTGTCTCTCTCA

[0549] CCTGGCAAGTGATGA

Claims

1. An mRNA molecule, characterized in that The mRNA molecule comprises a natural sequence or a codon-optimized sequence encoding an antigen sequence, wherein the antigen sequence comprises a plurality of novel coronavirus receptor binding domain (RBD) fragments and an immunoglobulin Fc fragment connected to the plurality of novel coronavirus RBD fragments, wherein the plurality of novel coronavirus RBD fragments are composed of two, three, four or five different novel coronavirus RBD fragments in series; the novel coronavirus RBD fragment is selected from the RBD fragment itself or a mutant thereof; Preferably, the novel coronavirus RBD fragments include: RBD prototype, RBD beta, RBD delta and RBDBA.

4.

2. The mRNA molecule according to claim 1, characterized in that The novel coronavirus RBD fragments are connected by a linker; preferably, the linker is a GG or GS sequence; preferably, the linker is a GGS, GGGS, GSGS, SGGS, GGGGS, GSGGS, GGSGS, GGSGGS, GGGSGS, GGGGGS, GGGSGGS or GGGGSGGGGSGGGGSGT sequence.

3. The mRNA molecule according to claim 1, characterized in that The C-terminus of the novel coronavirus receptor binding domain (RBD) fragment polymer is connected to the immunoglobulin Fc fragment.

4. The mRNA molecule according to any one of claims 1 to 3, characterized in that The amino acid sequence of the novel coronavirus RBD fragment comprises the amino acid sequence shown in SEQ ID NO.1-SEQ ID NO.4 or its sequence derivative.

5. The mRNA molecule according to any one of claims 1 to 3, characterized in that The gene sequence encoding the novel coronavirus RBD fragment includes the polynucleotide sequence shown in SEQ ID NO.5-SEQ ID NO.8 or its degenerate sequence.

6. The mRNA molecule according to any one of claims 1 to 3, characterized in that The connection between the multiple novel coronavirus RBD fragments and the immunoglobulin Fc fragment includes the following series modes: RBD prototype-RBD beta-Fc; RBDdelta-RBD BA.4-Fc; RBDBA.4-RBD delta-RBD prototype-Fc; RBD BA.4-RBD delta-RBDbeta-RBD prototype-Fc.

7. The mRNA molecule according to any one of claims 1 to 3, characterized in that The immunoglobulin Fc fragment may be derived from humans, mice, rabbits, cows, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs and other animals; preferably, the immunoglobulin Fc fragment is derived from the Fc fragment of human immunoglobulin.

8. The mRNA molecule according to any one of claims 1 to 3, characterized in that The immunoglobulin Fc fragment is an IgG Fc fragment, an IgA Fc fragment, an IgD Fc fragment, an IgE Fc fragment or an IgM Fc fragment.

9. The mRNA molecule according to claim 8, characterized in that The IgG Fc fragment includes an IgG1 Fc fragment, an IgG2 Fc fragment, an IgG3 Fc fragment, or an IgG4 Fc fragment.

10. The mRNA molecule according to claim 7, characterized in that The Fc fragment of the human immunoglobulin includes further modifications, including YTE mutation or LS mutation, etc., preferably YTE mutation.

11. The mRNA molecule according to any one of claims 1 to 3, characterized in that The amino acid sequence of the immunoglobulin Fc fragment comprises the amino acid sequence shown in SEQ ID NO.9 or SEQ ID NO.19 or a sequence derivative thereof.

12. The mRNA molecule according to any one of claims 1 to 3, characterized in that The gene sequence encoding the immunoglobulin Fc fragment comprises the polynucleotide sequence shown in SEQ ID NO.10 or SEQ ID NO.20 or a degenerate sequence thereof.

13. The mRNA molecule according to any one of claims 1 to 3, characterized in that The mRNA molecule comprises a sequence encoding the amino acid sequence shown in SEQ ID NO.11 to SEQ ID NO.14 or a sequence derivative thereof.

14. The mRNA molecule according to any one of claims 1 to 3, characterized in that The gene sequence encoding the mRNA molecule comprises the polynucleotide sequence shown in SEQ ID NO.15-SEQ ID NO.18 or a degenerate sequence thereof.

15. The mRNA molecule according to any one of claims 1 to 3, characterized in that The mRNA molecule further comprises one or more structural elements; preferably, the structural element is a 5' cap, a 5' UTR, a 3' UTR or a poly (A) tail; more preferably, the mRNA comprises the 5' cap, the 5' UTR, the 3' UTR and the poly (A) tail.

16. The mRNA molecule according to claim 15, characterized in that The specific capping structure of the 5' cap is β-S-ARCA (D1) (m27,2"-OGppSpG) or m27,3'-OGppp (m12'-O)ApG; and / or More preferably, the 5'UTR is the 5'-UTR sequence of human α-globin or β-globin mRNA, and optionally has an optimized "Kozak" sequence; and / or More preferably, the 3'UTR is a combination of two sequence elements (FI element) derived from the "split amino-terminal enhancer" (AES) mRNA (referred to as F) and the mitochondrial encoded 12S ribosomal RNA (referred to as I) placed between the coding sequence in the mRNA molecule of any one of claims 1 to 3, or the 3'-UTR is preferably one or two repeated 3'-UTRs of human β-globin mRNA; and / or More preferably, the poly(A)-tail is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 nucleotides in length; more preferably, the poly(A)-tail is 110 nucleotides in length and consists of a stretch of 30 adenosine residues, followed by a 10 nucleotide linker sequence (random nucleotides) and another 70 adenosine residues.

17. The mRNA molecule according to any one of claims 1 to 3, characterized in that The mRNA molecule is a chemically modified mRNA molecule, and at least one of the chemical modifications is selected from pseudouridine, N1-methyl pseudouridine, N1-ethyl pseudouridine, 2-thiourea, 4′-thiourea, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyluridine.

18. An mRNA vaccine, characterized in that: The mRNA vaccine comprises the mRNA molecule of any one of claims 1-17.

19. A method for preparing the mRNA vaccine according to claim 18, characterized in that: The method comprises: encapsulating the mRNA molecule according to any one of claims 1 to 17 into lipid nanoparticles (LNP).

20. A broad-spectrum novel coronavirus mRNA vaccine composition, characterized in that: The mRNA vaccine composition comprises at least 2 mRNA vaccines according to claim 18.

21. The mRNA vaccine composition of claim 20, characterized in that The mRNA vaccine composition is formulated or is to be formulated as a liquid, a solid or a combination thereof.

22. The mRNA vaccine composition of claim 21, characterized in that The mRNA vaccine composition is an mRNA-lipid nanoparticle (LNP) vaccine composition; More preferably, the LNP comprises ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-sn-glycero-3-phosphocholine and cholesterol.

23. A method for preparing the mRNA-LNP vaccine composition according to any one of claims 20 to 22, characterized in that: The method comprises any of the following steps: (i) mixing at least two mRNA molecules according to any one of claims 1 to 17 and loading them into LNP; or (ii) loading at least two mRNA molecules according to any one of claims 1 to 17 into LNPs and then mixing them.

24. Use of the mRNA molecule of any one of claims 1-17, the mRNA vaccine of claim 18, or the mRNA vaccine composition of any one of claims 20-22 in the preparation of a medicament for preventing / treating diseases caused by novel coronavirus infection.

25. The use according to claim 24, characterized in that The medicament may further comprise one or more pharmaceutically acceptable carriers, diluents and / or excipients.